- Home
- CYRX vs RGNX Comparison
CYRX vs RGNX Comparison
Compare CYRX & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYRX | RGNX |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | United States |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.3M | 418.1M |
| IPO Year | 2008 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CYRX | RGNX |
|---|---|---|
| Price | $7.96 | $7.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $12.94 | ★ $28.75 |
| AVG Volume (30 Days) | 425.4K | ★ 804.5K |
| Earning Date | 03-03-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | 18.08 |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $176,177,000.00 | $10,393,000.00 |
| Revenue This Year | $10.92 | $50.05 |
| Revenue Next Year | $8.08 | $23.31 |
| P/E Ratio | $5.86 | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $4.63 | $5.04 |
| 52 Week High | $11.45 | $16.19 |
Technical Indicators
Market Signals| Indicator | CYRX | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 42.35 | 39.95 |
| Support Level | $6.57 | $7.81 |
| Resistance Level | $8.52 | $9.28 |
| Average True Range (ATR) | 0.39 | 0.47 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 28.43 | 6.15 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.